The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD‑1) immune‑checkpoint‑inhibitor antibody, following …

Collecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer.
Recently, immune checkpoint inhibitors (ICI), anti‐programmed death‐1 (PD‐1) antibody …

Nivolumab therapy for metastatic collecting duct carcinoma a... : Medicine Nivolumab therapy
for metastatic collecting duct carcinoma after nephrectomy: A case report : Medicine Log in or …

Collecting duct carcinoma (CDC) of the kidney is a rare subtype of renal cell carcinoma
(RCC) arising from the distal collecting tubules, characterized by an aggressive phenotype …

Background Collecting duct carcinoma and sarcomatoid renal cell carcinoma are tumors
with poor prognosis. Immune checkpoint inhibitors have been established as the standard …

Results Imaging studies 3 months after initiating nivolumab revealed a partial response
(46% reduction in the size of target lesions, stable target lesions, and no new lesions) with …

An 80-year-old male patient was diagnosed to have squamous cell carcinoma of the lung
which had a high level of programmed death-ligand 1 (PD-L1) expression. He was …

Background: The BONSAI phase II trial recently demonstrated the activity of cabozantinib in
metastatic collecting duct patients. The outcomes of patients in this setting treated with …

Background Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have
quickly become standard of care for patients with advanced non-small cell lung cancer and …

Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor (ICI), is now widely
used to treat numerous cancers. Although most adverse effects related to ICIs are …